iExoKrasG12D are engineered exosomes for the delivery of siRNA targeting KRASG12D. Here the authors describe the results of a phase I trial of iExoKrasG12D in patients with metastatic pancreatic cancer, reporting safety and clinical activity, as well as immunological correlates informing on tumor immune microenvironment reprograming and future combination with immune checkpoint inhibitors.’
- Valerie S. Kalluri
- Brandon G. Smaglo
- Raghu Kalluri